Detalles de la búsqueda
1.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34450619
2.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis
; 23(2): 183-195, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36272432
3.
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Nat Commun
; 13(1): 7284, 2022 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36435798
4.
An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.
Clin Pharmacol Ther
; 111(3): 585-594, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34699618
5.
AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.
Trials
; 22(1): 487, 2021 Jul 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34311777
Resultados
1 -
5
de 5
1
Próxima >
>>